References
1. IDF Diabetes Аtlas. 8th ed. 2017.
2. Minokoshi Y., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002; 415 (6869): 339-43.
3. Yoon M.J., et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator activated receptor α. Diabetes. 2006; 55 (9): 2562-70.
4. Lamers D., et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011; 60 (7): 1917-25.
5. Sell H., et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specifi c release from adipose tissue in vivo and in vitro. Diabetes Care. 2013; 36 (12): 4083-90.
6. Ametov A.S. Diabetes mellitus type 2. Problems and solutions. 3rd edition, revision and supplement. Vol. 1. Moscow: GEOTAR-Media, 2015: 92-119. (in Russian)7. DeFronzo R. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58 (4): 773-95.
8. Drucker D. The biology of incretin hormones. Cell Metab. 2006; 3: 153-65.
9. Drucker D., Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368: 1696-705.
10. Meier J., Nauck M. Incretins and the development of type 2 diabetes. Curr Diab Rep. 2006; 6: 194-201.
11. Meier J., et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first degree relatives of patients with type 2 diabetes. Diabetes. 2001; 50: 2497-504.
12. Hojberg P.V., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia.2009; 52: 199-207.
13. Nauck M.A., et al. Incretin-based therapies. Viewpoints on the way to consensus. Diabetes Care. 2009; 32 (suppl 2): 223-31.
14. Van Genugten R., et al. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes Obes Metab. 2013; 15 (7): 593-606.
15. Derosa G., et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, p-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012; 98 (1): 51-60.
16. Aschner P., et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012; 379 (9833): 2262-9.
17. Antsiferov M.B., Ametov A.S. Innovative Hypoglycemic Therapy: A New Strategy For An Old Problem. Farmateka [Pharmateca]. 2013; 258 (5): 1-9. (in Russian)
18. Melanie J., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61: 2461-98.
19. Frias J.P., et al. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab. 2019; 21 (5): 1128-35.
20. Scott R., et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018; 20 (12): 2876-884.
21. Ametov A.S., Gusenbekova D.G. The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity. Sakharnyy diabet [Diabetes Mellitus]. 2015; 18 (3); 85-92. (in Russian)
22. Ametov A.S., Gusenbekova D.G. DPP-4-inhibitors and fat metabolism in patients with type 2 diabetes. www.intechopen.com/books/diabetes-and-its-com-plications/dpp-4-inhibitors-and-fatmetabolism-in-patients-with-type-2-diabetes
23. Ametov A.S., Gusenbekova D.G. Influence of IDPP-4 on fat metabolism in patients with type 2 diabetes. Int J Clin Exp Med Sci. 2018; 4 (6): 78-86.
24. Instruction for medical use of the drug Janumet long. (in Russian)